Clinical trial
Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload…
NCT00395629 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00395629 |
|---|---|
| Title | Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis |
| Official title | A Phase I/II Open Label, Dose Escalation Trial and a Six Month Extension to Explore the Safety and Efficacy of ICL670 in Patients With Iron Overload Resulting From Hereditary Hemochromatosis. |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Iron Overload, Hereditary Hemochromatosis |
| Intervention type | Drug |
| Interventions | Deferasirox (ICL670) |
| Enrollment | 49 |
| Start date | Aug 1, 2006 |
| Primary completion | Dec 1, 2007 |
| Completion | Mar 1, 2009 |
| First posted | Nov 3, 2006 |
| Last update posted | May 30, 2011 |
| Countries | Australia, Canada, France, Germany, Italy, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: